Josef Coresh Seminar, September 10, 2025

Value of the Information & Strength of the Argument

The seminar provides substantial value by synthesizing decades of epidemiological research on dementia, offering nuanced insights into lifetime risk and the impact of competing risks. The argumentation is solid, grounded in large cohort data (ARIC) and landmark trials (ACHIEVE, China Rural Hypertension Control). Coresh carefully explains methodological complexities, such as the difference between Kaplan-Meier and competing risk analyses, and the varying predictive power of risk factors by age. He also acknowledges limitations, such as the confounding of race and geography in ARIC. The presentation is persuasive in advocating for midlife prevention and the potential of biomarkers, while remaining cautious about overinterpretation.

Scientific Rigor, Source Quality, Title Accuracy

The seminar demonstrates high scientific rigor, with clear references to published studies and ongoing research. Coresh cites specific papers (e.g., Nature Medicine, Diabetes Care, JAMA) and discusses their findings critically. The quality of sources is excellent, relying on peer-reviewed literature and large cohort studies. The title accurately reflects the content, as it is a seminar by Josef Coresh. The presentation is well-organized, with a logical flow from lifetime risk to risk factors to biomarkers and trials. No comments were provided for analysis.

The title accurately reflects the content: a seminar by Josef Coresh, presented in a formal academic setting.

8/10

The seminar is delivered by a highly cited expert in epidemiology and population health, drawing on extensive data from the ARIC cohort and referencing landmark studies. The content is well-structured, transparent about methods and limitations, and aligns with current scientific consensus. However, as a seminar, it is primarily an expert synthesis rather than a peer-reviewed publication, and some claims are presented without full methodological detail.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 02:00Introduction by Albert Hofman, chair of Epidemiology, introducing Dr. Coresh.
• 05:00Coresh introduces the Optimal Aging Institute perspective on aging and function.
• 10:00Discussion of the ARIC cohort design and its relevance to dementia research.
• 15:00Presentation of lifetime risk of dementia estimates (42% in ARIC) and comparison with Framingham.
• 20:00Nuances of lifetime risk by sex, race, and APOE genotype, and the role of competing risks.
• 25:00Impact of midlife vascular risk factors on dementia risk and the paradox of lower risk factors leading to higher lifetime risk due to longer survival.
• 30:00Discussion of population attributable risk and how it varies by age of dementia onset.
• 35:00Introduction to blood biomarkers for dementia, including p-tau, NfL, and GFAP, and their associations with dementia risk.
• 40:00Overview of the ACHIEVE trial on hearing intervention and its findings on cognitive decline.
• 45:00Discussion of the China Rural Hypertension Control Project and its implications for dementia prevention.
• 50:00Concluding remarks on integrating biomarkers into prevention trials and future directions.

• Harvard Chan School of Public Health - Epidemiology Degree Program — Description of the video provides this link for more information about the department's degree programs.

• Lancet Commission on dementia prevention — Coresh references the Lancet Commission report as a landmark for modifiable risk factors.
• SPRINT MIND trial — Coresh mentions SPRINT MIND as a prior study on blood pressure lowering and cognitive outcomes.

• Framingham Heart Study lifetime risk estimate — Coresh notes that the Framingham estimate of 20% lifetime risk is lower than the ARIC estimate of 42%, possibly due to older data and methodological differences.